尼洛替尼治疗KIT突变转移性或不可手术黑色素瘤患者的疗效与安全性:全球单臂II期TEAM试验最终结果
TEAM单臂II期试验纳入42例未经KIT抑制剂治疗的KIT突变晚期黑色素瘤患者,接受尼洛替尼400 mg每日两次治疗,主要终点客观缓解率为26.2%(11/42;95%CI 13.9%-42.0%),达到拒绝无效假设的阈值,中位无进展生存期4.2个月、总生存期18.0个月,安全性及疗效与既往伊马替尼数据相似。
要点
- 尼洛替尼400 mg每日两次在KIT突变晚期黑色素瘤中客观缓解率26.2%(11/42;95%CI 13.9%-42.0%),均为部分缓解。
- 11例缓解者中10例携带外显子11突变,其中4例为L576P突变。
- 中位缓解持续时间7.1个月,中位无进展生存期4.2个月、总生存期18.0个月。
核心结论
- 尼洛替尼在晚期KIT突变黑色素瘤患者中的活性与既往伊马替尼治疗患者的历史数据相似。
- 与既往伊马替尼结果相似,尼洛替尼在外显子11突变(包括L576P)患者中显示出更强的活性,提示尼洛替尼可能成为特定KIT突变患者的有效治疗选择。
- DTIC治疗显示出潜在活性,但患者数量少限制了结果解读。
研究设计与样本
- 单臂II期TEAM试验纳入42例未经KIT抑制剂治疗的KIT突变晚期黑色素瘤患者,接受尼洛替尼400 mg每日两次治疗。
- TEAM最初设有达卡巴嗪(DTIC)对照臂,因观察到的KIT突变黑色素瘤数量少,方案修订为单臂试验;在方案修订去除该研究臂之前,有13例患者被随机分配至DTIC。
- 主要终点为根据实体瘤疗效评价标准判定的客观缓解率。
主要发现
- 客观缓解率为26.2%(n=11/42;95%CI 13.9%-42.0%),足以拒绝无效假设(ORR≤10%)。
- 所有观察到的缓解均为部分缓解,中位缓解持续时间为7.1个月。
- 20例(47.6%)患者疾病稳定,10例(23.8%)疾病进展,1例(2.4%)疗效未知。
- 11例缓解患者中10例携带外显子11突变,其中4例为L576P突变。
- 中位无进展生存期和总生存期分别为4.2个月和18.0个月。
临床怎么用
- 作者认为尼洛替尼可能成为特定KIT突变(包括外显子11突变及L576P)晚期黑色素瘤患者的有效治疗选择。
局限性
- DTIC治疗相关结果解读受患者数量少限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with KIT-mutated advanced melanoma without prior KIT inhibitor treatment. PATIENTS AND METHODS: Forty-two patients with KIT-mutated advanced melanoma were enrolled and treated with nilotinib 400 mg twice daily. TEAM originally included a comparator arm of dacarbazine (DTIC)-treated patients; the design was amended to a single-arm trial due to an observed low number of KIT-mutated melanomas. Thirteen patients were randomized to DTIC before the protocol amendment removing this study arm. The primary endpoint was objective response rate (ORR), determined according to Response Evaluation Criteria In Solid Tumors. RESULTS: ORR was 26.2% (n = 11/42; 95% CI, 13.9%-42.0%), sufficient to reject the null hypothesis (ORR ≤10%). All observed responses were partial responses (PRs; median response duration, 7.1 months). Twenty patients (47.6%) had stable disease and 10 (23.8%) had progressive disease; 1 (2.4%) response was unknown. Ten of the 11 responding patients had exon 11 mutations, four with an L576P mutation. The median progression-free survival and overall survival were 4.2 and 18.0 months, respectively. Three of the 13 patients on DTIC achieved a PR, and another patient had a PR following switch to nilotinib. CONCLUSION: Nilotinib activity in patients with advanced KIT-mutated melanoma was similar to historical data from imatinib-treated patients. DTIC treatment showed potential activity, although the low patient number limits interpretation. Similar to previously reported results with imatinib, nilotinib showed greater activity among patients with an exon 11 mutation, including L576P, suggesting that nilotinib may be an effective treatment option for patients with specific KIT mutations. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01028222.
引用
- Guo J, Carvajal RD, Dummer R, et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017. PMID: 28327988. doi:10.1093/annonc/mdx079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。